Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (95)	11/8/1998 10:02:00 PM
From: Mike McFarland	Read Replies (3) \| Respond to of 1386

No help? Okay then, well for newbies...here is what a half hour of research turned up; HU-211 equals Dexanabinol, it is one compound in a family of synthetic analogs of marijuana. It is not a human monoclonal antibody (now stop laughing out there), sometimes you see hu-xxx and I got all thrown off by that. So did anybody on the thread go to that 'Congress of Neurological Surgeons' Conference in Seattle? The press release doesn't seem to have enough for me to try and judge this thing..."Intracranial pressure above a threshold of 25 mmHg, an important risk factor and a predictor of poor neurological outcome, was significantly reduced in the drug-treated patients through the third day of treatment..." how much is "significantly" Neurological outcomes in the study, assessed periodically up to 6 months after injury, established a trend of efficacy. The percentage of patients achieving Good Neurological Outcome, the highest score on the five level Glasgow Outcome Scale used to assess the recovery of head trauma patients, was higher in the drug-treated group at each measurement. some numbers? Among the most severely injured patients in the study, a better outcome was consistently observed among the treated group than among the non-treated group. some more numbers? Mainly I just flounder around in these biotechs, for instance I have some ntii (xerecept/brain edema) so that is why pars caught my eye. It also helped that Castro started a new thread etc. Anyway, at this rate I will know if I like the stock in a year, hehe. --MM